(As of December 12, 2025 | Post Q3 2025 earnings and recent insider transactions)
Current market capitalization: ≈ $1.02 trillion (based on ~$1,076.50/share and 947.69 million shares outstanding)
Introduction
Eli Lilly and Company (NYSE: LLY), founded in 1876 by Colonel Eli Lilly as a pharmaceutical firm in Indianapolis, Indiana, is a global leader in developing medicines for diabetes (e.g., Mounjaro), obesity (Zepbound), oncology, immunology, and neuroscience. Public since 1978, it features a single-class share structure (one vote per share), aligning voting with economic ownership. The company became the first healthcare firm to hit $1T market cap in November 2025, driven by GLP-1 drugs generating ~$25.9B in the first nine months of 2025 (56% of revenue). Ownership is heavily institutional (~83%), with insiders ~0.16% (mostly executives), and retail ~17%. The Lilly Endowment (charitable arm of the founding family) anchors at ~10%. The table below details the top 10 economic shareholders from Q3 2025 13F filings (Sep 30, 2025) and SEC data, with values at current market cap. Recent activity includes $62.3M in insider sales (Nov 18, 2025) and ongoing buybacks ($5B authorized).
| Rank | Owner / Stakeholder | Ownership % | Approx. Value ($1.02T valuation) | Detailed Notes |
|---|---|---|---|---|
| 1 | Lilly Endowment Inc. (Founding Family Trust) | 10.10% | $103.0 billion | Largest shareholder; ~95.49M shares. Charitable foundation established in 1937 by the Lilly family; holds for philanthropic purposes (e.g., education, religion). Stable stake with minor trims (~0.3% in 2025); no voting control but symbolic governance influence. |
| 2 | Vanguard Group Inc. | 8.56% | $87.3 billion | Top institutional via index funds (e.g., VTI, VOO); owns ~80.96M shares. Passive with ~$9.3T AUM; added ~1.17M shares (+1.5%) in Q3 2025, core S&P 500 holding (~7% weighting). No direct control; focuses on pharma growth. |
| 3 | BlackRock Inc. | 6.96% | $71.0 billion | Holds ~65.81M shares through iShares ETFs (e.g., IVV); passive/active mix. Trimmed ~168K shares (-0.4%) in Q3 2025; board observer on governance/ESG. Key in healthcare funds; LLY ~3% of portfolio. |
| 4 | PNC Financial Services Group Inc. | 5.40% | $55.1 billion | ~51.1M shares; institutional holder via asset management. Slight cut (-0.02%) in 2025; focuses on stable dividend payers (LLY yields ~0.6%). Advisory on risk; ~5% of pharma exposure. |
| 5 | State Street Corporation | 3.70% | $37.7 billion | Owns ~34.5M shares via SPDRs (e.g., SPY); fully passive. Added ~64K shares (+0.2%) in Q3; votes proxies on exec comp and drug pricing ethics. ~4% of health holdings. |
| 6 | FMR LLC (Fidelity) | 3.50% | $35.7 billion | ~33.1M shares across funds (e.g., Contrafund); active with minor Q3 additions. Bullish on obesity pipeline (e.g., $1.3B Superluminal AI deal, Aug 2025); advisory on innovation. |
| 7 | Capital Research Global Investors | 2.80% | $28.6 billion | ~26.5M shares in growth strategies; active manager. Holds for long-term GLP-1 dominance; ~2% of portfolio; engaged on R&D sustainability. |
| 8 | Price T. Rowe Associates Inc. (T. Rowe Price) | 2.40% | $24.5 billion | ~22.7M shares in growth funds (e.g., Blue Chip); trimmed ~1% in Q3 on valuation. Focuses on neuroscience/oncology; board input on M&A. |
| 9 | Geode Capital Management, LLC | 2.20% | $22.4 billion | Fidelity affiliate with ~20.8M shares in index trackers; passive. Grew ~0.3% in Q3; tracks Nasdaq 100; minimal voting power. |
| 10 | David A. Ricks (CEO) | 0.03% | $0.3 billion | ~0.28M shares; largest active insider. Recent sales (~$10M in Nov 2025); oversees strategy since 2017; aligns with $63.5B FY2025 revenue guidance. |
Total Top 10 = ~45.65% | Remaining: Other Institutions (~38%), Other Insiders (~0.13%, e.g., Patrik Jonsson CFO at ~0.01%), Retail (~16%) | Grand Total = 100%
Conclusion
As of December 2025, Eli Lilly's ownership is institutionally dominated (~83% total) by passive leaders like Vanguard and BlackRock, providing stability for its $63.5B FY2025 revenue guidance (up ~25% YoY, 40% from incretins) and $15B+ net income, while the Lilly Endowment's ~10% stake honors its founding legacy amid expansions (e.g., Amazon delivery deal, Mar 2024). Retail's ~16% reflects investor enthusiasm for obesity treatments, but patent cliffs and pricing scrutiny (e.g., Texas lawsuit, Aug 2025) pose risks. With $1.02T market cap (up ~50% YoY) and $5B buybacks, expect ~0.5% annual share reductions, minor institutional rebalancing in Q4 13Fs (due Feb 2026), and growth from AI drug discovery. This structure supports innovation in a $1T+ pharma powerhouse. For filings, visit SEC EDGAR or Eli Lilly's investor relations.